Paradigm Biopharmaceuticals Engages Complementary Contract Research Organization to Support Knee Osteoarthritis Trial; Shares Fall 5%

MT Newswires Live

Nov 12, 2025

Paradigm Biopharmaceuticals (ASX:PAR) engaged Nordic Bioscience Clinical Development as a complementary contract research organization to support the firm's ongoing pivotal third phase PARA_OA_012 clinical trial in knee osteoarthritis, according to a Wednesday Australian bourse filing.

Nordic Bioscience will work collaboratively with Paradigm and Advanced Clinical, its global lead contract research organization, to activate and manage four additional clinical sites, one in Hong Kong and three in Moldova. These sites are expected to be activated in December and start recruitment in January 2026.

A clinical presence in Hong Kong will allow new drugs approved by a single recognized reference authority to apply for registration in Hong Kong under the recently introduced "1+" regulatory mechanism, provided supporting local clinical data and expert recognition are submitted.

Paradigm expects to finalize the activation of sites at around 60 globally.

The company's shares fell 5% in recent trading on Wednesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582387346"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582387346\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582387346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 13:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582387346","market":"hk","top_or_hot":-1,"title":"Paradigm Biopharmaceuticals Engages Complementary Contract Research Organization to Support Knee Osteoarthritis Trial; Shares Fall 5%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) engaged Nordic Bioscience Clinical Development as a complementary contract research organization to support the firm's ongoing pivotal third phase PARA_OA_012 clinical trial in knee osteoarthritis, according to a Wednesday Australian bourse filing.</p><p>Nordic Bioscience will work collaboratively with Paradigm and Advanced Clinical, its global lead contract research organization, to activate and manage four additional clinical sites, one in Hong Kong and three in Moldova. These sites are expected to be activated in December and start recruitment in January 2026.</p><p>A clinical presence in Hong Kong will allow new drugs approved by a single recognized reference authority to apply for registration in Hong Kong under the recently introduced \"1+\" regulatory mechanism, provided supporting local clinical data and expert recognition are submitted.</p><p>Paradigm expects to finalize the activation of sites at around 60 globally.</p><p>The company's shares fell 5% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Paradigm Biopharmaceuticals Engages Complementary Contract Research Organization to Support Knee Osteoarthritis Trial; Shares Fall 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nParadigm Biopharmaceuticals Engages Complementary Contract Research Organization to Support Knee Osteoarthritis Trial; Shares Fall 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-12 13:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PBIGF\">Paradigm Biopharmaceuticals</a> (ASX:PAR) engaged Nordic Bioscience Clinical Development as a complementary contract research organization to support the firm's ongoing pivotal third phase PARA_OA_012 clinical trial in knee osteoarthritis, according to a Wednesday Australian bourse filing.</p><p>Nordic Bioscience will work collaboratively with Paradigm and Advanced Clinical, its global lead contract research organization, to activate and manage four additional clinical sites, one in Hong Kong and three in Moldova. These sites are expected to be activated in December and start recruitment in January 2026.</p><p>A clinical presence in Hong Kong will allow new drugs approved by a single recognized reference authority to apply for registration in Hong Kong under the recently introduced \"1+\" regulatory mechanism, provided supporting local clinical data and expert recognition are submitted.</p><p>Paradigm expects to finalize the activation of sites at around 60 globally.</p><p>The company's shares fell 5% in recent trading on Wednesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2582387346","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582387346","pubTimestamp":1762923737,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Paradigm Biopharmaceuticals  engaged Nordic Bioscience Clinical Development as a complementary contract research organization to support the firm's ongoing pivotal third phase PARA_OA_012 clinical trial in knee osteoarthritis, according to a Wednesday Australian bourse filing.Nordic Bioscience will work collaboratively with Paradigm and Advanced Clinical, its global lead contract research organization, to activate and manage four additional clinical sites, one in Hong Kong and three in Moldova. These sites are expected to be activated in December and start recruitment in January 2026.A clinical presence in Hong Kong will allow new drugs approved by a single recognized reference authority to apply for registration in Hong Kong under the recently introduced \"1+\" regulatory mechanism, provided supporting local clinical data and expert recognition are submitted.Paradigm expects to finalize the activation of sites at around 60 globally.The company's shares fell 5% in recent trading on Wedne","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","PAR.AU":"PARADIGM BIOPHARMACEUTICALS","BK7508":"医药生物股"},"translate_title":"Paradigm Biopharmaceuticals聘请补充合同研究组织支持膝骨关节炎试验；股价下跌5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAR.AU":1},"content_text":"Paradigm Biopharmaceuticals (ASX:PAR) engaged Nordic Bioscience Clinical Development as a complementary contract research organization to support the firm's ongoing pivotal third phase PARA_OA_012 clinical trial in knee osteoarthritis, according to a Wednesday Australian bourse filing.Nordic Bioscience will work collaboratively with Paradigm and Advanced Clinical, its global lead contract research organization, to activate and manage four additional clinical sites, one in Hong Kong and three in Moldova. These sites are expected to be activated in December and start recruitment in January 2026.A clinical presence in Hong Kong will allow new drugs approved by a single recognized reference authority to apply for registration in Hong Kong under the recently introduced \"1+\" regulatory mechanism, provided supporting local clinical data and expert recognition are submitted.Paradigm expects to finalize the activation of sites at around 60 globally.The company's shares fell 5% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}